Have we successfully implemented CYP2D6 genotyping in psychiatry?

Research output: Contribution to journalEditorial

3 Scopus citations
Original languageEnglish
Pages (from-to)1201-1203
Number of pages3
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume13
Issue number12
DOIs
StatePublished - Dec 2 2017

Bibliographical note

Funding Information:
J de Leon has received researcher-initiated grants from Eli Lilly (one ended in 2003 and the other, as co-investigator, ended in 2007); from Roche Molecular Systems, Inc. (ended in 2007); and, in a collaboration with Genomas, Inc., from the NIH Small Business Innovation Research program (ended in 2010). He was on the advisory boards of Bristol-Myers Squibb (2003/04) and AstraZeneca (2003). Roche Molecular Systems supported one of his educational presentations, which was published in a peer-reviewed journal (2005). His lectures have been supported once by Sandoz (1997), twice by Lundbeck (1999 and 1999), twice by Pfizer (2001 and 2001), three times by Eli Lilly (2003, 2006, and 2006), twice by Janssen (2000 and 2006), once by Bristol-Myers Squibb (2006), and seven times by Roche Molecular Systems, Inc. (once in 2005 and six times in 2006). The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Keywords

  • Biological markers
  • United States Food and Drug Administration
  • cytochrome P-450 enzyme system/genetics
  • drug monitoring
  • genotype
  • mental disorders/drug therapy/genetics
  • pharmacogenetics
  • psychotropic drugs/therapeutic use

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Fingerprint

Dive into the research topics of 'Have we successfully implemented CYP2D6 genotyping in psychiatry?'. Together they form a unique fingerprint.

Cite this